Lifestyle Program for Atrial Fibrillation and Body Fat in Overweight Adults
Tests an exercise and diet program against usual care in overweight adults with atrial fibrillation.
Plain-language title generated from the registry record
Registry title: Exercise and Dietary Lifestyle Intervention on Reducing Atrial Fibrillation Burden, Cardiac and Body Fat Mass.
Key facts
- Where
- Jyväskylä, Kuopio, and Tampere, FinlandSee the 4 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07430007, who can take part
Where in Finland
- Hospital Nova of Central FinlandJyväskylä, FinlandTaking people
- Kuopio University HospitalKuopio, FinlandNot yet recruiting
- University Of Eastern FinlandKuopio, FinlandNot yet recruiting
- Tampere University HospitalTampere, FinlandNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Eastern Finland
- Trial code
- NCT07430007
- Record updated
- 24 February 2026
- Original description
Atrial fibrillation (AF) is the most common cardiac arrhythmia and is strongly associated with obesity and excess body fat. Lifestyle interventions, including exercise and dietary modification, may reduce AF burden, but long-term randomized controlled trial evidence with objective AF burden assessment and advanced cardiac imaging is limited.Read full original descriptionShow less
Effect of a Tailored Exercise and Dietary Lifestyle Intervention on Reducing Atrial Fibrillation Burden, Cardiac and Body Fat Mass in Overweight and Obese Patients. The MOVE-AF Ran-domized Clinical Trial
Atrial fibrillation (AF) is the most common cardiac arrhythmia and is strongly associated with obesity and excess body fat. Lifestyle interventions, including exercise and dietary modification, may reduce AF burden, but long-term randomized controlled trial evidence with objective AF burden assessment and advanced cardiac imaging is limited.
The MOVE-AF trial is a randomized controlled trial designed to evaluate whether a 12-month tailored exercise and dietary lifestyle intervention, compared with usual care, reduces atrial fibrillation burden and symptom severity and decreases cardiac and total body fat mass in overweight and obese adults with paroxysmal or persistent AF.
Inclusion: Age 18-75 years; Body mass index (BMI) ≥27 kg/m²; Documented atrial fibrillation (paroxysmal or persistent); Ability to participate in exercise training and follow study procedures; Access to a smartphone or device enabling rhythm monitoring; Provides written informed consent.
Exclusion: Participation in other lifestyle or drug weight reduction trials; Recent joint or back surgery within the past 6 months; Unstable angina pectoris or acute coronary syndrome within the past 3 months; Severe valvular heart disease or planned cardiac surgery; Severe heart failure (NYHA class IV) or severe angina (CCS class IV); Unstable coronary artery disease or recent myocardial infarction; Severe pulmonary disease limiting exercise capacity; Active malignancy; Autoimmune or systemic inflammatory diseases; Severe renal or hepatic failure; Memory disease or significant cognitive impairment; Unstable psychiatric condition; Contraindications to exercise testing or training, including cardiac symptoms or cardiovascular symptoms, making exercise unsafe; Any condition judged by investigators to make participation unsafe or infeasible; Significant left ventricular dysfunction (ejection fraction <30%); Permanent atrial fibrillation; Continuing back or joint pain symptoms and inability to take part in individualized exercise training; Pregnancy or breastfeeding; Participation in another interventional study.